Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Takeda, Portal Instruments partner to develop needle-free drug delivery device

Japan drugmaker Takeda has collaborated with medical device firm Portal Instruments to develop and commercialize needle-free drug delivery device.

Under the deal, the partnership will develop Portal’s needle-free drug delivery device for use with Takeda’s investigational or approved biologic medicines.

Portal’s needle-free drug delivery device will deliver the biologic through a pressurized liquid rather than a needle. It can be self-administered by patients at home.

As per terms of the deal, Portal will secure an initial payment, and is eligible to receive additional payments of up to $100m based on the achievement of specified development, regulatory and sales-based milestones and royalties

The Portal device has been developed at the Massachusetts Institute of Technology (MIT), which can be used across a range of biologic medicines that currently need administration through an injection.

Takeda’s first application of the device includes the investigational use with Entyvio (vedolizumab).

Entyvio is a monoclonal antibody for adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD), which is presently administered through intravenous infusion.

Currently, the company is carrying out a phase III clinical trial program, which is assessing the efficacy and safety of a subcutaneous formulation of vedolizumab in adults with moderately to severely active UC or CD.

Takeda global program and brand lead Stefan Koenig said:  “There is a need for options to keep improving the experience for patients with life-long, chronic conditions that are managed with the intravenous infusions of biologic medicines.”

Portal CEO Patrick Anquetil said: “This partnership allows us to work collaboratively with Takeda’s highly experienced R&D team and provides the first opportunity to introduce the Portal device to patients, a pivotal step as we continue to expand its potential and grow our business.”  


Image: The head office of Takeda Pharmaceutical Company, in Chuo-ku, Osaka. Photo: courtesy of J o.